Curis, Inc.

Curis Inc. announced encouraging outcomes from its TakeAim Leukemia study for Acute Myeloid Leukemia treatment with emavusertib, achieving 10 objective responses among 19 evaluable patients. The company faces profitability challenges but sees potential in emavusertib's novel mechanism and broader development program, including Orphan Drug Designations. Curis projects confidence in emavusertib's prospects despite development risks and undervalued stock.

Curis, Inc. will report Q3 2024 financial and operating results on Nov. 14, 2024, at 8:00 a.m. ET, followed by a conference call and webcast at 8:30 a.m. ET. Curis focuses on developing emavusertib, an orally available, small molecule IRAK4 inhibitor, currently in Phase 1/2 studies for various cancers.

Thomas A. Satterfield, Jr. files Schedule 13G reporting beneficial ownership of 690,432 shares of Curis, Inc., representing 8.05% of the class, filed under Rule 13d-1(c).